Literature DB >> 18691784

Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy.

Rocio Toro1, Leopoldo Perez-Isla, Griselda Doxastaquis, Miguel A Barba, Alberto Rivera Gallego, Guillem Pintos, Francisco-Javier Barbados, Alipio Mangas, Jose L Zamorano.   

Abstract

UNLABELLED: Fabry cardiomyopathy (FC) is characterized by left ventricular hypertrophy (LVH). The aim of this study is to determine whether early changes revealed by tissue Doppler imaging (TDI) are useful for detecting preclinical cardiac abnormalities in patients with this X-linked genetic disorder. If so, this tool could help in deciding whether to begin enzymatic therapy earlier than otherwise. METHODS AND
RESULTS: 59 consecutive patients with confirmed Fabry disease (FD) underwent conventional and TD echocardiography. FD patients with and without LVH had significantly lower early diastolic tissue Doppler velocities (Ea) compared with the control group (P<0.001); The isovolumic relaxation time (IVRT) was significantly longer in the FD group with LVH (P<0.001). Isovolumic contraction time (IVCT) was significantly shorter in the FD group without LVH compared with the control group (P<0.001). Additionally, peak systolic wall motion velocity (Sa) was significantly lower in patients with LVH, compared with those without LVH (P<0.001). The systolic myocardial velocity correlates inversely with septum and posterior wall thickness (r: -0.74 and r: -0.90; P<0.001 respectively). In respect of predicting preclinical cardiac impairment, the area under the ROC curve of 0.83 suggests an optimal IVRT cut-off point of 60 ms for separating early cardiac impairment from the established condition. This gives a 96.6% specificity rate for the early detection of cardiac involvement. The best parameter for detecting preclinical FC is the IVCT, with a cut-off point of 105 ms, which shows high sensitivity and specificity (100% and 91%, respectively; AUC: 0.97).
CONCLUSIONS: Myocardial contraction and relaxation evaluation confirms that TDI is a reliable method for early identification of preclinical FC, even before FC patients develop LVH.

Entities:  

Mesh:

Year:  2008        PMID: 18691784     DOI: 10.1016/j.ijcard.2008.04.075

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  11 in total

Review 1.  The genetics of dilated cardiomyopathy.

Authors:  Lisa Dellefave; Elizabeth M McNally
Journal:  Curr Opin Cardiol       Date:  2010-05       Impact factor: 2.161

2.  Early cardiovascular remodelling in Fabry disease.

Authors:  Luca Costanzo; Sergio Buccheri; Piera Capranzano; Luigi Di Pino; Giuseppina Curatolo; Margherita Rodolico; Stefano Leggio; Anita Blundo; Corrado Tamburino; Ines Monte
Journal:  J Inherit Metab Dis       Date:  2013-04-25       Impact factor: 4.982

Review 3.  Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.

Authors:  Brendan N Putko; Kevin Wen; Richard B Thompson; John Mullen; Miriam Shanks; Haran Yogasundaram; Consolato Sergi; Gavin Y Oudit
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

Review 4.  Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.

Authors:  R P Morrissey; K J Philip; E R Schwarz
Journal:  Cardiovasc J Afr       Date:  2011 Jan-Feb       Impact factor: 1.167

5.  Fabry Disease Presenting with Hypertrophic Cardiomyopathy and Tricuspid Regurgitation.

Authors:  Sang-Cheol Cho; Han-Wook Yoo; Jae Won Lee; Jeong Yoon Jang; Ran Heo; Jong-Min Song
Journal:  J Cardiovasc Ultrasound       Date:  2016-12-28

Review 6.  Biomarkers and Imaging Findings of Anderson-Fabry Disease-What We Know Now.

Authors:  Idalina Beirão; Ana Cabrita; Márcia Torres; Fernando Silva; Patrício Aguiar; Francisco Laranjeira; Ana Marta Gomes
Journal:  Diseases       Date:  2017-06-11

7.  Biomarkers of Myocardial Fibrosis: Revealing the Natural History of Fibrogenesis in Fabry Disease Cardiomyopathy.

Authors:  Patrício Aguiar; Olga Azevedo; Rui Pinto; Jacira Marino; Carlos Cardoso; Nuno Sousa; Damião Cunha; Derralynn Hughes; José Luís Ducla Soares
Journal:  J Am Heart Assoc       Date:  2018-03-13       Impact factor: 5.501

Review 8.  Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring.

Authors:  Björn Hoffmann
Journal:  Orphanet J Rare Dis       Date:  2009-10-11       Impact factor: 4.123

9.  Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data.

Authors:  Markus A Engelen; Eva Brand; Timo B Baumeister; T Marquardt; Thomas Duning; Nani Osada; Roland M Schaefer; Joerg Stypmann
Journal:  BMJ Open       Date:  2012-11-21       Impact factor: 2.692

10.  Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease.

Authors:  Aurelie Nguyen Dinh Cat; Brigitte Escoubet; Vincent Agrapart; Violaine Griol-Charhbili; Trenton Schoeb; Wenguang Feng; Edgar Jaimes; David G Warnock; Frederic Jaisser
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.